The Vaccination of people over 60 is progressing apace, with the aim that a end of this month of May, as the president of the Generalitat, Ximo Puig, has reiterated on several occasions, at least the entire population of this group is protected with at least one dose.
Currently 83.4% have already received an injection and the 41.5% are protected with the full guideline. In the case of those over 80 years, according to data from the Ministry of Health, one hundred percent have already had both vaccines and in the 79 to 70 age group, 91% already have one dose and more than half both. The group that lags the most is the 69 to 60 years, with 67% of people with the first dose and only 5% with the full regimen. In order to speed up the vaccination of this population group, the Ministry of Health has decided to use the Pfizer and Moderna vaccines for the 69 to 66-year-old group, since the waiting time between the two doses is shorter than with AstraZeneca.
Protect the group over 50 years of age against coronavirus is essential in order to reduce the mortality caused by the disease and reduce the care pressure in hospitals. In fact, according to data from the Ministry of Health itself, the most frequent age group currently in hospitals is that of people between 51 and 65 years of age (29.2%), followed at a short distance by the group of people of 66 to 75 years (28.4%) and over 75 years (26.8%). This last group before vaccination accounted for more than 40% of the coronavirus admissions.
On the other hand, the Valencian Community registered on Tuesday aa record number of two million doses administered since last December. About 28% of the population already have a dose and 13% are on a full schedule. The vast majority of vaccines that have arrived are from the Pfizer laboratory.
About 600,000 doses correspond to AstraZeneca, laboratory from which Europe will not buy more vaccines from June. From the Ministry of Health they minimize the impact that this decision will have on the rate of vaccination in the Valencian Community and point out that the doses of Pfizer y de Janssen cThey will compensate for this deficit. In recent weeks Pfizer has increased the number of vaccines it sends to the Valencian Community and there are already 175,000 that arrive every Monday. For its part, the laboratory that produces the Janssen serum has promised that two million doses will reach the Community by September within the commitment it has with the European Union. In addition, they recall from the Ministry of Health, that the ministry only authorizes the use of AstraZeneca for the population between 60 and 69 years old, so once this group is immunized, the vaccines from this laboratory would not be able to be used.
This week, the Anglo-Swedish pharmaceutical company has not sent vaccines, which has caused 105,000 fewer doses to be administered in the Valencian Community. Even so, the IFA and Ciudad de la Luz «vacunadromes» have remained open three days to vaccinate massively.
120,000 AstraZeneca injections in stock for second doses
The Department of Health have in stock 120,000 AstraZeneca vaccinations to finish vaccinating people who received the first dose weeks ago. It should be remembered that the Ministry of Health has decided to space, in the case of those under 60 years of age, the interval between the two doses from 12 to 16 weeks until deciding which vaccine they have just been immunized with. The decision depends on a study that is being carried out at the moment and the results of which will be known in the coming days. The Ministry of Health recalls that “it is not possible to know if the risk of serious thrombosis detected with this vaccine increases, remains the same or decreases with a second dose.” In the Valencian Community there are 190,000 people under the age of 60 who were vaccinated with AstraZeneca and 300,000 between the ages of 60 and 69 years. The decision on how to finish immunizing them will be known in a few days.
Eddie is an Australian news reporter with over 9 years in the industry and has published on Forbes and tech crunch.